Scarica l'app Stockscreener
83.22
2.41%
1.96
Dopo l'orario di chiusura:
83.00
-0.22
-0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
NKTR Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive - Seeking Alpha
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile
NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit — The Gross Law Firm - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
Nektar Therapeutics stock hits 52-week high at 78.95 USD By Investing.com - Investing.com Canada
Nektar Therapeutics stock hits 52-week high at 78.95 USD - Investing.com
Nektar Therapeutics stock (US6354171056): Is its immunology pipeline strong enough to unlock new ups - AD HOC NEWS
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Certain Restricted Stock Unit of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Stock Options of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Common Stock of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Nektar Therapeutics (HAM:ITH0) Stock Price & 30 Year Financial Data - GuruFocus
NKTR Shareholder Alert: Nektar Therapeutics Securities Class Action Lawsuit Investors With ... - Bluefield Daily Telegraph
NKTR Shareholder Alert: Nektar Therapeutics Securities - GlobeNewswire
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - Morningstar
Nektar Therapeutics stock: What investors need to know in immunotherapy's next wave - AD HOC NEWS
Press releases provided by CNW - Techaeris
A Look At Nektar Therapeutics (NKTR) Valuation After Rezpegaldesleukin Trial Progress And Litigation Concerns - Sahm
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Secu - GuruFocus
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Oppo - GuruFocus
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire
Lawsuit filed for Investors who lost money with shares of Nektar Therapeutics (NASDAQ: NKTR) - openPR.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Nektar Therapeutics to Contact the Firm Today! - ACCESS Newswire
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein - GlobeNewswire
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire
NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm - Sahm
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - GlobeNewswire Inc.
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile
Nektar (NKTR) Poised for Potential Upside with Upcoming Data Rel - GuruFocus
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $123 - 富途牛牛
Nektar Goes Silent: What's Behind The Quiet Period? - RTTNews
Citi Adds Nektar Therapeutics (NKTR) to 30-Day Upside Catalyst Watch List - StreetInsider
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Holzer & Holzer Reminds Investors of Lead Plaintiff Deadlines in Shareholder Lawsuits - National Today
Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline - National Today
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff - GlobeNewswire
H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Cuts Target Price to $135 - 富途牛牛
Nektar Therapeutics (NKTR) stock price, news, quote and history - Yahoo Finance UK
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Nektar Therapeutics (NKTR) Is Up 12.1% After REZPEG Data And Lawsuits CollideHas The Bull Case Changed? - Yahoo Finance
Do Rezpegaldesleukin Lawsuits Reframe Nektar Therapeutics' (NKTR) Core Risk Narrative Around Trial Integrity? - simplywall.st
NKTR PE Ratio & Valuation, Is NKTR Overvalued - Intellectia AI
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):